EP1292311A2 - Combinaison d'un antidepresseur et d'un potentialisateur des recepteurs ampa pour traiter la depression - Google Patents

Combinaison d'un antidepresseur et d'un potentialisateur des recepteurs ampa pour traiter la depression

Info

Publication number
EP1292311A2
EP1292311A2 EP01934874A EP01934874A EP1292311A2 EP 1292311 A2 EP1292311 A2 EP 1292311A2 EP 01934874 A EP01934874 A EP 01934874A EP 01934874 A EP01934874 A EP 01934874A EP 1292311 A2 EP1292311 A2 EP 1292311A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
amine
methylethyl
methylsulfonyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01934874A
Other languages
German (de)
English (en)
Inventor
Phil Skolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1292311A2 publication Critical patent/EP1292311A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • EAA receptors excitatory amino acid receptors
  • Excitatory amino acid receptors are classified into two general types. Receptors that are directly coupled to the opening of cation channels in the cell o membrane of the neurons are termed "ionotropic". This type of receptor has been subdivided into at least three subtypes, which are defined by the selective agonists /V-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid (AMPA), and kainic acid (KA).
  • NMDA selective /V-methyl-D-aspartate
  • AMPA alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid
  • KA kainic acid
  • the second general type of receptor is the G-protein or second messenger-linked 5 "metabotropic" excitatory amino acid receptor.
  • This second type of EAA receptor is coupled to multiple second messenger systems that lead to enhanced phosphoinositide hydrolysis, activation of phospholipase D, increases or decreases in c-AMP formation, and changes in ion channel function.
  • Schoepp and Conn Trends in Pharmacol. Sci., 14, 13 (1993). Both types of receptors o appear not only to mediate normal synaptic transmission along excitatory pathways, but also participate in the modification of synaptic connections during development and throughout life.
  • Schoepp, Bockaert, and Sladeczek Trends in Pharmacol. Sci., 11 , 508 (1990); McDonald and Johnson, Brain Research Reviews, 15, 41 (1990).
  • the AMPA subtype of glutamate receptors are assembled from four protein subunits known as GluR1 to GluR4, (also referred to as GluRA-GluRD) while kainic acid receptors are assembled from the subunits GluR5 to GluR7, and KA-1 and KA-2. Wong and Mayer, Molecular Pharmacology 44: 505-510, 1993. It is not yet known how these sub-units are combined in the natural state. However, the structures of certain human variants of each subunit have been elucidated, and cell lines expressing individual subunit variants have been cloned and incorporated into test systems designed to identify compounds which bind to or interact with them, and hence which may modulate their function.
  • European patent application, publication number EP-A2-0574257 discloses the human sub-unit variants GluRIB, GluR2B, GluR3A and GluR3B.
  • European patent application, publication number EP-A1 -0583917 discloses the human subunit variant GluR4B.
  • AMPA and kainic acid receptors are their rapid deactivation and desensitization in response to application of glutamate. Yamada and Tang, The Journal of Neuroscience, September 1993, 13(9): 3904- 3915 and Kathryn M. Partin, J. Neuroscience, November 1 , 1996, 16(21): 6634- 6647. The physiological implications of rapid desensitization, and deactivation if any, are not fully understood.
  • AMPA and/or kainic acid receptors may be inhibited using certain compounds. This action of these compounds is often referred to in the alternative as "potentiation" of the receptors.
  • One such compound, which selectively potentiates AMPA receptor function, is cyclothiazide. Partin et al., Neuron. Vol. 11 , 1069-1082, 1993.
  • Depression in its many variations has recently become much more visible to the general public than it has previously been. It is now recognized as an extremely damaging disorder, and one that afflicts a surprisingly large fraction of the population. Suicide is the most extreme symptom of depression, but millions of people, not quite so drastically afflicted, live in misery and partial or complete uselessness, and afflict their families as well by their affliction.
  • the introduction of fluoxetine, a serotonin reuptake inhibitor (SRI) was a breakthrough in the treatment of depression, and depressives are now much more likely to be diagnosed and treated than they were only a decade ago.
  • Depression is often associated with other diseases and conditions, or caused by such other conditions. For example, it is associated with Parkinson's disease; with HIV; with Alzheimer's disease; and with abuse of anabolic steroids. Depression may also be associated with abuse of any substance, or may be associated with behavioral problems resulting from or occurring in combination with head injuries, mental retardation or stroke.
  • serotonin reuptake inhibitors Despite the breakthrough nature of serotonin reuptake inhibitors in the treatment of depression, a number of patients suffering from depression do not respond, or respond only partially to treatment with serotonin reuptake inhibitors, for example, or other traditional modes of treating depression, including the older tricyclic class of compounds referred to as monoamine oxidase inhibitors (MAOI's). Additionally, there is often a significant period of time before treatment with serotonin reuptake inhibitors provide a therapeutic effect. Furthermore, various side effects are sometimes associated with current antidepressant therapy, for example with serotonin reuptake inhibitors the gastrointestinal system may be affected wherein symptoms are often manifested as nausea and occasional vomiting.
  • MAOI's monoamine oxidase inhibitors
  • the present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.
  • the present invention further provides a method for treating refractory ; depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.
  • This invention provides, further, a method for attenuating adverse events associated with depression comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a suitable AMPA receptor potentiator.
  • This invention also provides a method of providing rapid onset treatment of depression to a patient which comprises administering to said patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is.a suitable AMPA receptor potentiator.
  • the invention also provides a pharmaceutical composition which comprises a first component which is a suitable antidepressant, and a second component which is a suitable AMPA receptor potentiator, the two components being present in an amount effective in the treatment of depression.
  • the present invention further provides an article of manufacture comprising packaging material and a pharmaceutical composition which comprises a first component which is a suitable antidepressant, and a second component which is a suitable AMPA receptor potentiator, contained within said packaging material, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating depression.
  • BRIEF DESCRIPTION OF THE DRAWING Figure 1 discloses the effect of the combination of imipramine and N-2-(4-(3-thienyl)phenylpropyl 2-propanesulfonamide (392098) in the Forced Swim Test in the mouse. More specifically, low doses of 392098 by itself produced no effect in the Forced Swim Test.
  • Figure 1 further reveals that when 392098 was combined at a dose as low as 25 micrograms/kg with a subeffective dose of imipramine (5 mg/kg), a statistically significant reduction in immobility of the mouse resulted.
  • glutamate receptor function refers to any increased responsiveness of glutamate receptors, for example AMPA receptors, to glutamate or an agonist, and includes but is not limited to inhibition of rapid desensitization or deactivation of AMPA receptors to glutamate.
  • AMPA receptor potentiator refers to a compound which inhibits the rapid desensitization or deactivation of AMPA receptors to glutamate.
  • the term "attenuating” means decreasing the number, severity or frequency of side effects or adverse events associated with treatment of depression with conventional antidepressant medication, such as an SRI's, when such products are used at dosages that yield beneficial effects on the symptoms of the disease.
  • the number “392098” refers to the compound N-2-(4-(3- thienyl)phenylpropyl 2-propanesulfonamide of example 2.
  • IMI imipramine
  • the term “FST” refers to Forced Swim Test.
  • the term “i.p.” refers to intraperitoneal or intraperitoneally. It is understood by one of ordinary skill in the art that the present invention includes the pharmaceutically acceptable salts of either or both of the first and second components.
  • the compounds used in this invention can possess a sufficiently acidic group, a sufficiently basic group, or both functional groups, and accordingly react with any of a number of organic and inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt refers to salts of the compounds used in the present invention which are substantially non-toxic to living organisms.
  • Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable mineral or organic acid. Such salts are also known as acid addition salts. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2-19 (1977) which are known to the skilled artisan.
  • Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • organic acids such as p-toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and
  • salts examples include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprate, caprylate, acrylate, ascorbate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, propionate, phenylpropionate, salicylate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, mandelate, nicotinate, isonicotinate, cinnamate, hippurate, nitrate, phthalate, teraphthalate, butyne-1 ,4- dioate, butyne-1 ,4- dioate
  • Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
  • bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
  • the potassium and sodium salt forms are particularly preferred. It should be recognized that the particular counterion forming a part of any salt of this invention is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
  • the above salts may form hydrates or exist in a substantially anhydrous form.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three- dimensional structures which are not interchangeable. The three-dimensional structures are called configurations.
  • enantiomer refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another.
  • chiral center refers to a carbon atom to which four different groups are attached.
  • diastereomers refers to stereoisomers which are not enantiomers.
  • racemate two diastereomers which have a different configuration at only one chiral center are referred to herein as “epimers”.
  • racemate racemic mixture
  • racemic modification refer to a mixture of equal parts of enantiomers.
  • enantiomeric enrichment refers to the increase in the amount of one enantiomer as compared to the other.
  • a convenient method of expressing the enantiomeric enrichment achieved is the concept of enantiomeric excess, or "ee”, which is found using the following equation:
  • E 1 is the amount of the first enantiomer and E 2 is the amount of the second enantiomer.
  • E 1 is the amount of the first enantiomer and E 2 is the amount of the second enantiomer.
  • the ee with respect to the first enantiomer is 40%.
  • the final ratio is 90:10, the ee with respect to the first enantiomer is 80%.
  • An ee of greater than 90% is preferred, an ee of greater than 95% is most preferred and an ee of greater than 99% is most especially preferred.
  • Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column.
  • separation and isolation of the compounds of the present invention into the individual enantiomers is similarly performed by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column, or other standard resolving techniques.
  • Choice of the appropriate chiral column, eluent and conditions necessary to effect separation of the enantiomeric pair is well within the knowledge of one of ordinary skill in the art.
  • the enantiomers of compounds of the present invention can be resolved using standard techniques such as those described by J. Jacques, et al., "Enantiomers. Racemates. and Resolutions". John Wiley and
  • Some of the compounds of the present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of the present invention.
  • the terms "R” and "S” are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center.
  • R rectus
  • S sinister
  • the priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in "Nomenclature of Organic Compounds: Principles and Practice", (J.H. Fletcher, et al., eds., 1974) at pages 103-120.
  • CX516 refers to a compound of the following structure:
  • the first component is a compound which functions as a suitable antidepressant.
  • suitable antidepressant includes but is not limited to serotonin reuptake inhibitors (SRI's), norepinephrine reuptake inhibitors (NERI's), combined serotonin-norepinephrine reuptake inhibitors (SNRI's), monoamine oxidase inhibitors (MAOI's), phosphodiesterase-4 inhibitors (PDE-4), and the like.
  • SRI's and SNRI's are the preferred suitable antidepressants, with SRI's being most preferred. More specifically, examples of suitable antidepressants include, but are not limited to:
  • Fluoxetine N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
  • U.S. Patent 4,314,081 is an early reference on the compound. Robertson et al., J. Med. Chem. 31. 1412 (1988), taught the separation of the R and S enantiomers of fluoxetine and showed that their activity as serotonin uptake inhibitors is similar to each other.
  • fluoxetine will be used to mean any acid addition salt or the free base, and to include either the racemic mixture or either of the R and S enantiomers;
  • Duloxetine N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, is usually administered as the hydrochloride salt and as the (+) enantiomer. It was first taught by U.S. Patent 4,956,388, which shows its high potency.
  • duloxetine will be used here to refer to any acid addition salt or the free base of the molecule; Venlafaxine is known in the literature, and its method of synthesis and its activity as an inhibitor of serotonin and norepinephrine uptake are taught by U.S. Patent 4,761 ,501. Venlafaxine is identified as compound A in that patent;
  • Citalopram 1 -[3-(dimethylamino)propyl]-1 -(4-fluorophenyl)-1 ,3-dihydro-5- isobenzofurancarbonitrile, is disclosed in U.S. Patent 4,136,193 as a serotonin reuptake inhibitor. Its pharmacology was disclosed by Christensen et al., Eur. J. Pharmacol. 41. 153 (1977), and reports of its clinical effectiveness in depression may be found in Dufour et al., Int. Clin. Psvchopharmacol.
  • Sertraline (1 S-cis)-4-(3,4-dichlorophenyl)-1 ,2,3,4-tetrahydro-N-methyl-1 - naphthylamine hydrochloride, is a serotonin reuptake inhibitor which is marketed as an antidepressant. It is disclosed by U.S. Patent 4,536,518;
  • Buproprion (Wellbutrin ® ), (+)-1-(3-chlorophenyl)-2-[(1 ,1- dimethylethyl)amino]-1-propanone is indicated for treatment of depression.
  • Reboxetine (EdronaxTM), 2-[ ⁇ -(2-ethoxy)phenoxy-benzyl]morpholine, is usually administered as the racemate. It was first taught by U.S. Patent 4,229,449, which describes its utility for the treatment of depression. Reboxetine is a selective norepinephrine reuptake inhibitor. The term "reboxetine” will be used here to refer to any acid addition salt or the free base of the molecule existing as the racemate or either enantiomer;
  • the second component is a compound which is a suitable AMPA potentiator.
  • suitable AMPA receptor potentiators include but are not limited to those disclosed in: WO 98/33496 published August 6, 1998;
  • AMPA receptor potentiators are listed in table I.
  • the title compound can be prepared following the procedure disclosed in WO 98/33496 published August 6, 1998, Example 51). More specifically, to a room temperature solution of 0.1 g (0.3 mmol) of N-2-(4-(4-(2- aminoethyl)phenyl)phenyl)propyl 2-propanesulfonamide (prepared following procedure disclosed in WO 98/33496 published August 6, 1998, Example 50) and 0.06 mL (0.4 mmol) of triethylamine in 2 mL of dichloromethane was added 0.03 mL (0.4 mmol) of methanesulfonyl chloride. The mixture was stirred at ambient temperature for 16 hours. Chromatography (10 g silica gel, 50% ethyl acetate/hexane) of the reaction mixture afforded 0.1 g (94%) of the title compound.
  • Example 1a Preparation of ((2R)-2-f4-(4-(2- r(methylsulfonyl)aminolethyl>phenv ⁇ phenyllpropyl)[(methylethv ⁇ sulfonvnamine.
  • the reaction mixture was cooled to 30° C and a 10% aqueous solution of NaHS0 3 (220 mL) was added dropwise while maintaining the temperature between 25° C and 30 ° C.
  • the mixture crystallized to a solid mass upon cooling to 0-5 °C.
  • the solids were suction filtered and rinsed with H 2 0 to afford 61 ,7 g of crude solids that were redissolved into warm MTBE (500 mL). This solution was extracted with H 2 0 (2 x 200 mL) and saturated NaHC0 3 (1 x 200 mL) and the organic phase was dried (MgS0 4 ), filtered, and concentrated under reduced pressure to -200 mL.
  • Potassium hydroxide pellets (85%, 143 g, 2.16 moles) were added to neutralized the sulfuric acid and then enough saturated aqueous sodium sulfite was added to decolorize the mixture to afford a white suspension.
  • the suspension was cooled to 15 °C and filtered.
  • the filter cake was triturated thoroughly with water and was then dissolved in CH 2 CI 2 (1 L) and extracted with additional water (2 x 200 mL).
  • the organic phase was concentrated under reduced pressure to provide the intermediate title compound, [2-(4-iodophenyl)ethyl](methylsulfonyl)amine, (201 g, 60.2%) as a white powder.
  • the reaction mixture was concentrated to a fluid oil that was partitioned between MTBE (500 mL) and water (500 mL). The organic phase was separated and washed with water (2 x 200 mL) and concentrated to a residue that was partially dissolved with heptane (1 L). The heptane soluble fraction was filtered through Celite ® 521 and concentrated to an oil (95 g). The residue was dissolved in acetone (600 mL) and heptane (600 mL) and filtered through Celite ® 521.
  • potassium formate 112.8 g, 1.34 moles, 5.1 eq
  • water 200 mL
  • Potassium carbonate 72.7g, 0.526 mol, 2.0 eq
  • 4- ⁇ 2-[(methylsulfonyl)amino]ethyl ⁇ benzene boronic acid 60.8 g, 0.250 mol, 0.95 eq
  • 1-propanol 7720 mL
  • Example 2 Alternative preparation of ⁇ (2R)-2-f4-(4- ⁇ 2- [(methylsulfonyl)amino1ethyl>phenyl)phenyl]propyl ⁇ [(methylethyl)sulfonyllamine.
  • the aqueous phase was extracted with CH 2 CI 2 (100 mL) and MTBE (2 x 100 mL).
  • the combined oily product and organic phases were adjusted to pH 12.5 with the addition of 1 N NaOH.
  • the phases were separated, and the organic phase was extracted with 1 N NaOH (100 mL) and water (2 x 100 mL).
  • HPLC analysis (60% CH 3 CN / 40% H 2 0, 2 mL / min, Zorbax C-18, 205 nm) of the organic phase indicated that the product had been removed from this phase.
  • the aqueous phases (containing product) were finally combined and washed with CH 2 CI 2 (100 mL) and MTBE (2 x 100 mL).
  • the aqueous phase was added to CH 2 CI 2 (450 mL) and 1 N H 2 SO 4 was added until the aqueous phase was at pH 3.05.
  • the phases were separated and the aqueous phase was extracted with CH 2 CI 2 (100 mL).
  • the combined organic extracts (containing product) were concentrated to an oil (58.5 g) that crystallized overnight.
  • the aqueous phase was back extracted with EtOAc (300 mL) and the combined organic phases (1500 mL) were dried (MgS0 4 ), filtered, and concentrated to a volume of about 620 mL within a 3 L round-bottom flask.
  • the clear, pale yellow solution was stirred slowly while heating to 60 °C.
  • Heptane 400 mL was added dropwise from a separatory funnel to the stirring EtOAc solution at 60 °C (17 volumes of EtOAc / 11 volumes of heptane). The heptanes were added over a period of 1.5 h and the clear, pale yellow solution was allowed to cool slowly with slow stirring overnight.
  • This material was purified via silica gel chromatography employing the Chromatotron and using a 4000 micron rotor while eluting with a gradient solvent of hexane/ethyl acetate 9:1 to hexane/ethyl acetate 3:1 to yield [2-fluoro-2-(4-iodophenyl)propyl][(methylethyl)sulfonyl]amine
  • the desired product was extracted with ethyl acetate and the organic layer was separated and washed twice with H 2 O, dried over K 2 CO 3 , and concentrated under reduced vacuum to yield the crude material (276 mg) as a dark oil.
  • the resulting oil was purified via silica gel chromatography employing the Chromatotron using a 4000 micron rotor and eluting with a solvent of
  • the ability of compounds to potentiate glutamate receptor-mediated response may be determined using fluorescent calcium indicator dyes (Molecular Probes, Eugene, Oregon, Fluo-3) and by measuring glutamate-evoked efflux of calcium into GluR4 transfected HEK293 cells, as described in more detail below.
  • 96 well plates containing confluent monolayers of HEK 293 cells stably expressing human GluR4B (obtained as described in European Patent Application Publication Number EP-A1 -583917) are prepared.
  • the tissue culture medium in the wells is then discarded, and the wells are each washed once with 200 ⁇ l of buffer (glucose, 10mM, sodium chloride, 138mM, magnesium chloride, 1 mM, potassium chloride, 5mM, calcium chloride, 5mM, N-[2- hydroxyethyl]-piperazine-N-[2-ethanesulfonic acid], 10mM, to pH 7.1 to 7.3).
  • buffer glucose, 10mM, sodium chloride, 138mM, magnesium chloride, 1 mM, potassium chloride, 5mM, calcium chloride, 5mM, N-[2- hydroxyethyl]-piperazine-N-[2-ethanesulfonic acid], 10mM, to pH 7.1 to
  • the plates are then incubated for 60 minutes in the dark with 20 ⁇ M Fluo3-AM dye (obtained from Molecular Probes Inc., Eugene, Oregon) in buffer in each well. After the incubation, each well is washed once with 100 ⁇ l buffer, 200 ⁇ l of buffer is added and the plates are incubated for 30 minutes.
  • 20 ⁇ M Fluo3-AM dye obtained from Molecular Probes Inc., Eugene, Oregon
  • Solutions for use in the test are also prepared as follows. 30 ⁇ M, 10 ⁇ M, 3 ⁇ M and 1 ⁇ M dilutions of test compound are prepared using buffer from a 10 mM solution of test compound in DMSO. 100 ⁇ M cyclothiazide solution is prepared by adding 3 ⁇ l of 100 mM cyclothiazide to 3 ml of buffer. Control buffer solution is prepared by adding 1.5 ⁇ l DMSO to 498.5 ⁇ l of buffer.
  • Each test is then performed as follows. 200 ⁇ l of control buffer in each well is discarded and replaced with 45 ⁇ l of control buffer solution. A baseline fluorescent measurement is taken using a FLUOROSKAN II fluorimeter (Obtained from Labsystems, Needham Heights, MA, USA, a Division of Life Sciences International Pic). The buffer is then removed and replaced with 45 ⁇ l of buffer and 45 ⁇ l of test compound in buffer in appropriate wells. A second fluorescent reading is taken after 5 minutes incubation. 15 ⁇ l of 400 ⁇ M glutamate solution is then added to each well (final glutamate concentration 100 ⁇ M), and a third reading is taken.
  • test compounds and cyclothiazide solutions are determined by subtracting the second from the third reading (fluorescence due to addition of glutamate in the presence or absence of test compound or cyclothiazide) and are expressed relative to enhance fluorescence produced by 100 ⁇ M cyclothiazide.
  • HEK293 cells stably expressing human GluR4 are used in the electrophysiological characterization of AMPA receptor potentiators.
  • recording pipettes have a resistance of 2-3 M ⁇ .
  • Using the whole-cell voltage clamp technique Hamill et al.(1981)Pfl ⁇ gers Arch., 391 : 85-100), cells are voltage-clamped at -60mV and control current responses to 1 mM glutamate are evoked.
  • the concentration of the test compound, both in the bathing solution and co-applied with glutamate is increased in half log units until the maximum effect was seen. Data collected in this manner are fit to the Hill equation, yielding an EC50 value, indicative of the potency of the test compound.
  • Reversibility of test compound activity is determined by assessing control glutamate 1 mM responses. Once the control responses to the glutamate challenge are re-established, the potentiation of these responses by 100 ⁇ M cyclothiazide is determined by its inclusion in both the bathing solution and the glutamate-containing solution. In this manner, the efficacy of the test compound relative to that of cyclothiazide can be determined.
  • the diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale which are well known to one of ordinary skill in the art. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to as the DSM-N manual published by the American Psychiatric Association, 1994.
  • FST Forced Swim Test
  • a male mouse typically weighing 25-30 g is placed in a clear plastic cylinder (diameter: 10 cm; height: 25 cm) filled with 6 cm of water (22-25°C) for six min. The duration of immobility during the last four minutes of the six minute test period is scored.
  • a mouse is recorded as immobile when floating motionless or making only those movements necessary to keep its head above water.
  • Administration of clinically effective antidepressants before this test e.g. imipramine, 15 mg/kg, administered intraperitoneally 15 min prior to testing
  • typically produce a diminution in the time immobile e.g. Trullas and Skolnick, European Journal of Pharmacology, 185, 1-10 (1990)).
  • mice can be injected intraperitoneally (in, e.g., 0.1 ml) with a suitable AMPA receptor potentiator and a suitable antidepressant (in e.g., 0.1 ml) at doses that do not individually produce a significant reduction in immobility.
  • a suitable AMPA receptor potentiator and a suitable antidepressant in e.g., 0.1 ml
  • a combination of these compounds if an augmentation (synergism) exists, would result in an effect greater than each agent alone.
  • increasing doses of either compound would be injected in the presence of a fixed (subeffective or marginally effective) dose of the second compound.
  • the same general strategy can be applied to the forced swim test as carried out in rats (below) as well as the tail suspension test, also described below.
  • a rat for example, a male Sprague Dawley rat from Harlan Sprague-Dawley
  • a clear plastic cylinder diameter: 18 cm; height: 40 cm filled with water (22-25°C) to a depth of 16 cm for fifteen min.
  • rat After testing, the rat is dried with paper towels and placed in holding cages. Five minutes later, animals receive intraperitoneal injections (0.1 ml) of drugs or vehicle, and are then returned to their home cages. On the following day, rats receive a second dose of compound(s) or vehicle 1 h prior to the test. The rats are placed in cylinders as described above for 5 min and the duration of immobility recorded.
  • Figure 1 discloses that low doses of 392098 by itself (0.025-0.1 mg/kg) produced no effect in the Forced Swim Test in mice.
  • the minimum effective dose (MED) of 392098 was 0.5 mg/kg, i.p.
  • Figure 1 further reveals that when 392098 was combined at a dose as low as 25 micrograms/kg with a subeffective dose of imipramine (5 mg/kg), a statistically significant reduction in immobility of the mouse resulted. Moreover, Figure 1 reveals an unexpected shift in the dose response curve of 392098 of at least 20-fold when it was administered in combination with a subeffective dose of imipramine.
  • the dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient.
  • the term "effective amount" is the amount or dose of each component, the suitable antidepressant and the suitable AMPA receptor potentiator, which provides the desired effect in the patient under diagnosis or particular treatment, such as treatment for depression.
  • An effective amount can be readily determined by the attending 5 diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances.
  • a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or l o involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • the attending diagnostician including, but not limited to: the species of mammal; its size, age, and general health; the specific disease or disorder involved; the degree of or l o involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • General outlines of the dosages, and some preferred dosages are set forth below.
  • a typical daily dose of the first component which is a suitable antidepressant will contain from about 0.01 mg/kg to about 100 mg/kg of the first component.
  • daily doses will be about 0.05 mg/kg to about 50 mg/kg, 20 more preferably from about 0.1 mg/kg to about 25 mg/kg. More specific dosages of certain suitable antidepressants are as follows:
  • Fluoxetine from about 1 to about 80 mg, once/day; preferred, from about 10 to about 40 mg once/day;
  • Duloxetine from about 1 to about 30 mg once/day; preferred, from 25 about 5 to about 20 mg once/day;
  • Venlafaxine from about 10 to about 150 mg once-thrice/day; preferred, from about 25 to about 125 mg thrice/day;
  • Milnacipran from about 10 to about 100 mg once-twice/day; preferred, from about 25 to about 50 mg twice/day; 30 Citalopram: from about 5 to about 50 mg once/day; preferred, from about 10 to about 30 mg once/day;
  • Fluvoxamine from about 20 to about 500 mg once/day; preferred, from about 50 to about 300 mg once/day; Paroxetine: from about 20 to about 50 mg once/day; preferred, from about 20 to about 30 mg once/day.
  • Sertraline from about 20 to about 500 mg once/day; preferred, from about 50 to about 200 mg once/day.
  • Reboxetine from about 1 to about 30 mg, once to four times/day; preferred, from about 5 to about 30 mg once/day.
  • Buproprion from about 100 to about 300 mg/day.
  • a typical daily dose of the second component which is a suitable AMPA receptor potentiator will contain from about 5 micrograms to about 150 mg of the suitable AMPA receptor potentiator, preferably about 5 micrograms to about 50 mg of the suitable AMPA receptor potentiator.
  • the term "patient” refers to a mammal such as a dog, rat, mouse, human, and the like.
  • the preferred patient is a human.
  • the adjunctive therapy of the present invention is carried out by administering the first component together with the second component in any manner which provides effective levels of the compounds in the body at the same time.
  • the compounds concerned are normally administered orally, and so oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately.
  • oral administration is not the only route or even the only preferred route.
  • transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine.
  • One of the drugs may be administered by one route, such as oral, and the others may be administered by the transdermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances.
  • the route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver.
  • adjunctive combination may be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both compounds are important embodiments of the present invention.
  • Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred.
  • Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered.
  • Each adjunctive dosage unit may contain the daily doses of all compounds, or may contain a fraction of the daily doses, such as one-third of the doses.
  • each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compounds. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compounds.
  • each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given.
  • the inert ingredients and manner of formulation of the adjunctive pharmaceutical compositions are conventional, except for the presence of the combination of the present invention.
  • the usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions.
  • compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used.
  • the amount of the compounds is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the patient in need of such treatment.
  • the activity of the adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition.
  • Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules;
  • the usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.
  • Tablets are prepared by direct compression, by wet granulation, or 5. by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are0 substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
  • a lubricant is necessary in a tablet formulation to prevent the tablet5 and punches from sticking in the die.
  • the lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
  • Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, o celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate. 5 Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acid environments, and soluble in basic environments.
  • Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose 0 phthalate and hydroxypropyl methylcellulose acetate succinate. It is preferred to formulate duloxetine and duloxetine-containing combinations as enteric compositions, and even more preferred to formulate them as enteric pellets.
  • a preferred duloxetine enteric formulation is a pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer. This enteric formulation is described in U.S. Patent No. 5,508,276, herein incorporated by reference in its entirety.
  • Tablets are often coated with sugar as a flavor and sealant.
  • the compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice.
  • Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients.
  • Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly.
  • Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also.
  • Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with innumerable pores through which the drugs are pumped by osmotic action.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une technique permettant de traiter la dépression, consistant à administrer à un patient une quantité efficace d'un premier composant antidépresseur adapté, associé à une quantité efficace d'un second composant qui est un agent de potentialisation du récepteur AMPA adapté.
EP01934874A 2000-05-24 2001-05-11 Combinaison d'un antidepresseur et d'un potentialisateur des recepteurs ampa pour traiter la depression Withdrawn EP1292311A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20682500P 2000-05-24 2000-05-24
US206825P 2000-05-24
PCT/US2001/011768 WO2001089530A2 (fr) 2000-05-24 2001-05-11 Therapie de combinaison pour le traitement de la depression

Publications (1)

Publication Number Publication Date
EP1292311A2 true EP1292311A2 (fr) 2003-03-19

Family

ID=22768136

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01934874A Withdrawn EP1292311A2 (fr) 2000-05-24 2001-05-11 Combinaison d'un antidepresseur et d'un potentialisateur des recepteurs ampa pour traiter la depression

Country Status (5)

Country Link
EP (1) EP1292311A2 (fr)
JP (1) JP2004509843A (fr)
AU (1) AU2001261022A1 (fr)
CA (1) CA2410531A1 (fr)
WO (1) WO2001089530A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US4148896A (en) * 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0189530A2 *

Also Published As

Publication number Publication date
WO2001089530A3 (fr) 2002-09-12
JP2004509843A (ja) 2004-04-02
CA2410531A1 (fr) 2001-11-29
AU2001261022A1 (en) 2001-12-03
WO2001089530A2 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
JP6078059B2 (ja) 置換シンナムアミド誘導体、その製造方法及び使用
TW200817360A (en) EP2 agonists
US6500865B1 (en) Sulfonamide derivatives
US6703425B2 (en) Sulfonamide derivatives
HUP0201157A2 (en) Monofluoroalkyl derivatives
CA2402288A1 (fr) Derives de naphtaline et leur utilisation pharmaceutique
JP2004511540A (ja) シクロアルキルフルオロスルホンアミド誘導体
EP1313719A2 (fr) Derives sulfonamides heterocycliques et leur utilisation pour accroitre la fonction du recepteur glutaminique
US20030225127A1 (en) Heterocyclic sulfonamide derivatives
US20030092770A1 (en) Combination therapy for treatment of depression
WO2001089530A2 (fr) Therapie de combinaison pour le traitement de la depression
US6515026B2 (en) Sulphonamide derivatives
CZ20023796A3 (cs) Sulfonamidové deriváty
EP0937708B1 (fr) Dérivés de sulfonamide
US20030225163A1 (en) Sulfonamide derivatives
WO2002089848A2 (fr) Methode de traitement du diabete
WO2002018329A1 (fr) Derives de sulfonamide acetylenique
WO2003032974A2 (fr) Utilisation de derives du sulfamide comme composes pharmaceutiques
US8716350B2 (en) Compositions and methods for the treatment of somatosensory disorders
EP1330233A1 (fr) Procede relatif au traitement de l'accident vasculaire cerebral
US12582719B2 (en) Chimeric compounds and methods of managing neurological disorders or conditions
WO2001094306A2 (fr) Derives de (bis)sulfonamide
WO2005013961A1 (fr) Polytherapie pour le traitement de troubles cognitifs ou de psychoses
US20040147612A1 (en) Sulfonamide derivatives
HK1024459A (en) Sulphonamide derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030312

17Q First examination report despatched

Effective date: 20041203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060607